Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2004

 
 
 
  • Anderegg TR, Jones RN, Sader HS. Quality Control Working Group. Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used. J Clin Microbiol. 2004; 42(7): 3356–8. 
  • Appelbaum P, Hoellman D, Jacobs M. MIC determination of the anti-pneumococcal activity of BAL9141 compared to other agents. 14th ECCMID 2004. Poster P537.  
  • Azoulay-Dupuis E, Bedos JP, Mohler J, Schmitt-Hoffmann A, Schleimer M, Shapiro S. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother. 2004; 48(4): 1105–11.  
  • Bogdanovich T, Bozdogan B, Appelbaum PC. Resistance Selection Studies on Staphylococci with Ceftobiprole (BAL9141). 44th ICAAC 2004. Poster E-2018.  
  • Clark L, Kosowska K, Credito K, Appelbaum PC. Resistance Selection of BAL9141, the Active Component of Prodrug BAL5788, against Pneumococci. 44th ICAAC 2004. Poster E-2020.  
  • Deshpande LM, Rhomberg PR, Fritsche TR, Sader HS and Jones RN. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis. 2004; 50(1): 73–5.  
  • Ednie L, Appelbaum PC. Antistaphylococcal Activity of Ceftobiprole (BAL9141) and Comparators. 44th ICAAC 2004. Poster E-2021.  
  • Galm U, Heller S, Shapiro S, Page M, Li S-M, Heide L. Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis. Antimicrobial Agents and Chemotherapy 2004; 48(4): 1307–1312.  
  • Goodall JJ, Chen GJ, Page MGP. Essential role of histidine 20 in the catalytic mechanism of Escherichia coli peptidyl-tRNA hydrolase. Biochemistry 2004; 43(15): 4583–4591.  
  • Guillen J, Bernabeu A, Shapiro S, Villalain J. Location and orientation of Triclosan in phospholipid model membranes. European Biophysics Journal 2004; 33(5): 448–453.  
  • Heep M, Querner S, Harsch M, O'Riordan W. Ceftobiprloe (BAL5788), the First of a New Class of Anti-MRSA Cephalosporins: Microbiological Results from a Phase II Study in Complicated Skin and Skin Structure Infections. 44th ICAAC 2004. Poster L-361.  
  • Heller S, Marrer E, Page MGP, Shapiro S, Thenoz L. Development of endogenous resistance by staphylococci to BAL9141 and comparators. 14th ECCMID 2004. Poster: P675.  
  • Hoellman D, Jacobs, M., Appelbaum, P. MIC determination of the anti-pneumococcal activity of BAL9141 compared to other agents. 14th ECCMID 2004. Poster P537.  
  • Jacobs MR, Bajaksouzian S, Windau A, Appelbaum PC. Ceftobiprole (BAL9141): Activity Against Staphylococci and Pneumococci by Microdilution and Etest Methods. 44th ICAAC. Poster D-1920.  
  • Kresken M, Heep M, Wiegand I. Gram-negative bacteria producing characterised beta-lactamases: in vitro activities of BAL9141 and comparators, 14th ECCMID 2004. Poster P536.  
  • Kresken M, Heep M. In vitro activities of BAL9141 and seven other beta-lactam antimicrobial agents towards clinical isolates of 12 members of the Enterobacteriaceae family. 14th ECCMID 2004. Poster P1209.  
  • Kresken M, Heep M. In Vitro Activities of BAL9141, the Active Component of BAL5788, and Seven other Beta-Lactams against Selected Strains of Pseudomonas aeruginosa Susceptible or Resistant to Ceftazidime. 14th ECCMID 2004. Poster E-2022.  
  • Lin G, Appelbaum PC. Comparative Time-Kill Determination of the Antipneumococcal Activity of Ceftobiprole (BAL9141). 14th ECCMID 2004. Poster E-2019.  
  • Mouton JW, Schmitt-Hoffmann A, Punt N. Monte Carlo Simulations of BAL8557: a New Watersoluble Azole with Antifungal Activity. 44th ICAAC 2004. Poster A-134.  
  • Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother. 2004; 48(5): 1713–8.  
  • Paetzel M, Goodall JJ, Kania M, Dalbey RE, Page MGP. Crystallographic and Biophysical Analysis of a Bacterial Signal Peptidase in Complex with a Lipopeptide-based Inhibitor. Journal of Biological Chemistry. 2004; 279(29): 30781–30790.  
  • Page MG. Cephalosporins in clinical development. Expert Opin Investig Drugs. 2004; 13(8): 973–85.  
  • Reynolds D, Livermore RM. Comparative Activity of BAL9141, Daptomycin and Linezolid versus S. aureus from Bacteremias in the UK and Ireland. 44th ICAAC 2004. Poster E-2035.  
  • Reynolds R, Livermore DM. Effect of Culture Conditions on MICs of BAL9141, Representing a New Class of Cephalosporins Active against MRSA. 44th ICAAC 2004. Abstact E-2036.  
  • Rice LB, Bellais S, Carias LL, Hutton-Thomas R, Bonomo RA, Caspers P, Page MGP, Gutmann L. Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium. Antimicrobial Agents and Chemotherapy 2004; 48(8): 3028–3032.  
  • Rouse M, Anguita-Alonso P, Hein MH, Steckelberg JM, Patel R. Activity of BAL5788 in Haemophilus influenzae, Enterobacter cloacae or Klebsiella pneumoniae Experimental Murine Pneumonia. 44th ICAAC 2004. Poster B-1177.  
  • Sader HS, Biedenbach DJ, Jones RN. Antimicrobial Activity of BAL9141Tested against Staphylococcal Strains with Selected Resistance Patterns. 44th ICAAC 2004. Poster E-2037.  
  • Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, Brown T, Man A, Weidekamm E. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004; 48(7): 2576-8.  
  • Schmitt-Hoffmann A, Roos B, Heep M, et al. Pharmacokinetics of BAL4815, a New Azole Antifungal after Administration of Single Ascending Intravenous Doses of its Pro-Drug BAL8557. 14th ECCMID 2004. Poster P-1033.  
  • Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Man A, Roehrle M. Pharmacokinetics of BAL4815, a New Azole Antifungal, after Administration of Single Ascending Intravenous Doses of its Pro-Drug BAL8557. 14th ECCMID 2004. Poster P1033.  
  • Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, Kovacs P. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004; 48(7): 2570–5.  
  • Schmitt-Hoffmann A, Roos B, Spickermann J, Weidekamm E, Roehrle M. Multiple Ascending Dose Pharmacokinetics of the New Antifungal BAL4815 after Intravenous and Oral Administration of its Prodrug BAL8557. 44th ICAAC 2004. Poster A-37.  
  • Schmitt-Hoffmann AH, Harsch M, Heep M, Schleimer M, Brown T, Man A, O'Riordan W. BAL5788 in patients with complicated skin and skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients, 14th ECCMID 2004. Poster P1031.  
  • Schmitt-Hoffmann AH, Roos B, Heep M, Schleimer M, Weidekamm E, Man A, Abdou N. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of Pro-drug BAL5788. 14th ECCMID 2004. Poster P1030.  
  • Schmitt-Hoffmann AH, Roos B, Schleimer M, Weidekamm E, Brown T, Heep M, Man A, Nilsson LG. Dose adjustment in subjects with normal and impaired renal function based on the pharmacokinetics of BAL5788. 14th ECCMID 2004. Poster P1032.  
  • Suzuki T, Nakasato K, Shapiro S, Pomati F, Neilan, BA. Effects of synthetic anaesthetics on the growth of the cyanobacterium Synechococcus leopoliensis. Journal of Applied Phycology 2004; 16(2): 145-152.  
  • Suzuki T, Suzuki K, Shapiro S, Nagano A. Effects of bioactive substances on the growth of lithotrophic ammonia-oxidizing bacteria. Toyo Daigaku Kiyo, Shizen Kagaku-hen 2004; 48: 11–18.  
  • Te Dorsthorst D, Verweij PE, Meis JF, Mouton JW. Pharmacodynamics of BAL4815 a new azole antifungal in a mouse model of systemic infection. 14th ECCMID 2004. Poster A-1874.  
  • Vaudaux BP, Gjinovci A, Bento M, Li D, Francois P, Lew DP, Schrenzel J. Poster Intensive Therapy with BAL5788 of Experimental Foreign Body Infection due to Methicillin-Resistant Staphylococcus aureus (MRSA). 44th ICAAC 2004. Poster B-677.  
  • Warn P, Sharp A, Denning D, Heep M, Schmitt-Hoffmann A. In vivo Activity of a new triazole BAL8557, the water-soluble prodrug of BAL4815, in a temporarily neutropenic murine model of disseminated Aspergillus flavus. Advances Against Aspergillosis Conference, San Francisco, 2004.  
  • Warn PA, Sharp A, Denning DW. In Vitro Activity of a New Triazole BAL4815, the Active Component of BAL8557 (the Water-Soluble Prodrug) against Aspergillus spp. 44th ICAAC 2004. Poster F-842.
  • Beyer D, Kroll HP, Endermann R, Schiffer G, Siegel S, Bauser M, Pohlmann J, Brands M, Ziegelbauer K, Haebich D, Eymann C, Brotz-Oesterhelt H. New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob Agents Chemother. 2004; 48(2): 525-32.
  • Freiberg C, Brunner NA, Schiffer G, Lampe T, Pohlmann J, Brands M, Raabe M, Habich D, Ziegelbauer K. Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J Biol Chem. 2004; 279(25): 26066-73.
  • Pohlmann Jens, Brotz-Oesterhelt H. New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disord. 2004; 4(4): 261-72.
 
Info